{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:54:28Z","timestamp":1791258868128,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104816","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:12:24Z","timestamp":1790320344000},"page":"104816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Strength of weakness in molecular interactions: toward transient medicines in drug discovery"],"prefix":"10.1016","volume":"31","author":[{"given":"Sten","family":"Ohlson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104816_b0005","first-page":"1","article-title":"Quantitative fragmentomics allow affinity mapping of interactomes","volume":"13","author":"Gogl","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104816_b0010","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41586-020-2188-x","article-title":"A reference map of the human binary protein interactome","volume":"580","author":"Luck","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104816_b0015","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cell.2015.09.053","article-title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances","volume":"163","author":"Hein","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104816_b0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.drudis.2008.02.001","article-title":"Designing transient binding drugs: a new concept for drug discovery","volume":"13","author":"Ohlson","year":"2008","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104816_b0025","first-page":"488","article-title":"The importance of drug-target residence time","volume":"12","author":"Zhang","year":"2009","journal-title":"Curr Opin Drug Discov Dev"},{"key":"10.1016\/j.drudis.2026.104816_b0030","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.immuni.2014.10.008","article-title":"Leukocyte migration into inflamed tissues","volume":"41","author":"Nourshargh","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2026.104816_b0035","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","article-title":"Avidity in antibody effector functions and biotherapeutic drug design","volume":"21","author":"Oostindie","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104816_b0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrm.2017.16","article-title":"The mystery of membrane organization: composition, regulation and roles of lipid rafts","volume":"18","author":"Sezgin","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.drudis.2026.104816_b0045","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41586-022-05673-2","article-title":"Reducing affinity as a strategy to boost immunomodulatory antibody agonism","volume":"614","author":"Yu","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104816_b0050","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0968-0004(00)01550-4","article-title":"Macromolecular interactions: tracing the roots","volume":"25","author":"Srere","year":"2000","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.drudis.2026.104816_b0055","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1091\/mbc.e14-06-1035","article-title":"Challenges and dreams: physics of weak interactions essential to life","volume":"25","author":"Chien","year":"2014","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.drudis.2026.104816_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fchem.2020.603259","article-title":"Current methods for detecting cell membrane transient interactions","volume":"8","author":"Bagheri","year":"2020","journal-title":"Front Chem"},{"key":"10.1016\/j.drudis.2026.104816_b0065","doi-asserted-by":"crossref","first-page":"9331","DOI":"10.1021\/acs.chemrev.1c01023","article-title":"NMR provides unique insight into the functional dynamics and interactions of intrinsically disordered proteins","volume":"122","author":"Camacho-Zarco","year":"2022","journal-title":"Chem Rev"},{"key":"10.1016\/j.drudis.2026.104816_b0070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s42004-025-01542-x","article-title":"NMR-driven structure-based drug discovery by unveiling molecular interactions","volume":"8","author":"Platzer","year":"2025","journal-title":"Commun Chem"},{"key":"10.1016\/j.drudis.2026.104816_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2023.117079","article-title":"Surface plasmon resonance technology: recent advances, applications and experimental cases","volume":"163","author":"Capelli","year":"2023","journal-title":"Trends Anal Chem"},{"key":"10.1016\/j.drudis.2026.104816_b0080","first-page":"882","article-title":"Real-time SPR biosensing to detect and characterize fast dissociation rate binding interactions missed by endpoint detection and implications for off-target toxicity screening","volume":"15","author":"Martelly","year":"2025","journal-title":"Biomol"},{"key":"10.1016\/j.drudis.2026.104816_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2024.117741","article-title":"Biolayer interferometry and its applications in drug discovery and development","volume":"176","author":"Jug","year":"2024","journal-title":"Trends Anal Chem"},{"key":"10.1016\/j.drudis.2026.104816_b0090","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ymeth.2024.03.007","article-title":"Isothermal titration calorimetry and surface plasmon resonance methods to probe protein\u2013protein interactions","volume":"225","author":"Upadhyay","year":"2024","journal-title":"Methods"},{"key":"10.1016\/j.drudis.2026.104816_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2023.117161","article-title":"Advances in analytical technologies detecting and characterizing noncovalent interactions for fragment-based drug discovery","volume":"166","author":"Davoine","year":"2023","journal-title":"Trends Anal Chem"},{"key":"10.1016\/j.drudis.2026.104816_b0100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymeth.2018.01.011","article-title":"Fragment screening for drug leads by weak affinity chromatography (WAC-MS)","volume":"146","author":"Ohlson","year":"2018","journal-title":"Methods"},{"key":"10.1016\/j.drudis.2026.104816_b0105","first-page":"2270","article-title":"Fragment-based drug discovery campaigns guided by native mass spectrometry","volume":"15","author":"Sternicki","year":"2024","journal-title":"RSC MedChem"},{"key":"10.1016\/j.drudis.2026.104816_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2025.101065","article-title":"State-of-the-art and future directions in structural proteomics","author":"Happonen","year":"2025","journal-title":"Mol Cell Proteom"},{"key":"10.1016\/j.drudis.2026.104816_b0115","doi-asserted-by":"crossref","first-page":"7672","DOI":"10.3390\/ijms23147672","article-title":"Microscale thermophoresis as a tool to study protein interactions and their implication in human diseases","volume":"23","author":"Magnez","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104816_b0120","first-page":"727","article-title":"Techniques for the analysis of protein-protein interactions in vivo","volume":"171","author":"Xing","year":"2016","journal-title":"Plant Phys"},{"key":"10.1016\/j.drudis.2026.104816_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijbiomac.2023.124089","article-title":"Recent advances in sensing the inter-biomolecular interactions at the nanoscale \u2013 a comprehensive review of AFM-based force spectroscopy","volume":"238","author":"Lostao","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2026.104816_b0130","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3390\/biophysica2040047","article-title":"Optical tweezers to force information out of biological and synthetic systems one molecule at a time","volume":"2","author":"Bocanegra","year":"2022","journal-title":"Biophysica"},{"key":"10.1016\/j.drudis.2026.104816_b0135","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/bs.mcb.2021.12.006","article-title":"Proximity labeling for investigating protein-protein interactions","volume":"169","author":"Conrad","year":"2022","journal-title":"Meth Cell Biol"},{"key":"10.1016\/j.drudis.2026.104816_b0140","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/abio.2001.5019","article-title":"Prediction of affinity and kinetics in biomolecular interactions by affinity chromatography","volume":"291","author":"Leickt","year":"2001","journal-title":"Anal Biochem"},{"key":"10.1016\/j.drudis.2026.104816_b0145","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1021\/jacsau.4c00123","article-title":"Accurate characterization of binding kinetics and allosteric mechanisms for the HSP90 chaperone inhibitors using AI-augmented integrative biophysical studies","volume":"4","author":"Xu","year":"2024","journal-title":"JACS Au"},{"key":"10.1016\/j.drudis.2026.104816_b0150","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nsb0596-427","article-title":"Rapid, Electrostatically assisted association of proteins","volume":"3","author":"Schreiber","year":"1996","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.drudis.2026.104816_b0155","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF03256679","article-title":"Applications of binding kinetics to drug discovery: translation of binding mechanisms to clinically differentiated therapeutic responses","volume":"22","author":"Swinney","year":"2008","journal-title":"Pharm Med"},{"key":"10.1016\/j.drudis.2026.104816_b0160","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrd1958","article-title":"Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond","volume":"5","author":"Lipton","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104816_b0165","first-page":"161","article-title":"Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action","volume":"25","author":"Kapur","year":"2000","journal-title":"J Psych Neurosci"},{"key":"10.1016\/j.drudis.2026.104816_b0170","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1146\/annurev-pharmtox-032320-015420","article-title":"Novel therapeutic approach for excitatory\/inhibitory imbalance in neurodevelopmental and neurodegenerative diseases","volume":"61","author":"Swagata","year":"2021","journal-title":"Ann Rev Pharm Tox"},{"key":"10.1016\/j.drudis.2026.104816_b0175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1602\/neurorx.1.1.101","article-title":"Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults","volume":"1","author":"Stuart","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/j.drudis.2026.104816_b0180","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/428473a","article-title":"Turning down, but not off","volume":"428","author":"Lipton","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104816_b0185","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.drudis.2006.04.012","article-title":"The dose makes the medicine","volume":"11","author":"Stumpf","year":"2006","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104816_b0190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1021\/acsptsci.0c00012","article-title":"Implications of ligand\u2013receptor binding kinetics for therapeutic targeting of G protein-coupled receptors: implications of ligand-receptor binding kinetics for therapeutic targeting of G protein-coupled receptors","volume":"3","author":"Velden","year":"2020","journal-title":"ACS Pharma Trans Sci"},{"key":"10.1016\/j.drudis.2026.104816_b0195","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/11209070-000000000-00000","article-title":"Tranexamic acid","volume":"72","author":"McCormack","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104816_b0200","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"Hopkins","year":"2008","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104816_b0205","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104816_b0210","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1021\/jm400856t","article-title":"Polypharmacology \u2013 foe or friend?","volume":"56","author":"Peters","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104816_b0215","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s43440-025-00715-8","article-title":"Polypharmacology: new drugs in 2023\u20132024","volume":"77","author":"Ryszkiewicz","year":"2025","journal-title":"Pharma Rep"},{"key":"10.1016\/j.drudis.2026.104816_b0220","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/437942a","article-title":"Drug discovery: playing dirty","volume":"437","author":"Frantz","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104816_b0225","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrd2582","article-title":"Paul Ehrlich: founder of chemotherapy","volume":"7","author":"Kaufmann","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104816_b0230","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104816_b0235","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.tips.2005.02.007","article-title":"The efficiency of multi-target drugs: the network approach might help drug design","volume":"26","author":"Csermely","year":"2005","journal-title":"Trends Pharm Sci"},{"key":"10.1016\/j.drudis.2026.104816_b0240","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.pharmthera.2013.01.016","article-title":"Structure and dynamics of molecular networks: a novel paradigm of drug discovery","volume":"138","author":"Csermely","year":"2013","journal-title":"Pharm Ther"},{"key":"10.1016\/j.drudis.2026.104816_b0245","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s007260070042","article-title":"Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents \u2013 toward an understanding of their favorable tolerability","volume":"19","author":"Rogawski","year":"2000","journal-title":"Amino Acids"},{"key":"10.1016\/j.drudis.2026.104816_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2015.00205","article-title":"Multi-target pharmacology: possibilities and limitations of the \u201cskeleton key approach\u201d from a medicinal chemist perspective","volume":"6","author":"Talevi","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104816_b0255","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nbt1338","article-title":"Drug\u2013target network","volume":"25","author":"Y\u0131ld\u0131r\u0131m","year":"2007","journal-title":"Nat Biotech"},{"key":"10.1016\/j.drudis.2026.104816_b0260","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.tips.2009.07.004","article-title":"Conciliating binding efficiency and polypharmacology","volume":"30","author":"Mestres","year":"2009","journal-title":"Trends Pharm Sci"},{"key":"10.1016\/j.drudis.2026.104816_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharm Res"},{"key":"10.1016\/j.drudis.2026.104816_b0270","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1002\/ptr.8217","article-title":"Luteolin: a promising multifunctional natural flavonoid for human diseases","volume":"38","author":"Mingtao","year":"2024","journal-title":"Phyto Res"},{"key":"10.1016\/j.drudis.2026.104816_b0275","first-page":"321","article-title":"Weak-binding molecules are not drugs? \u2013 toward a systematic strategy for finding effective weak-binding drugs","volume":"18","author":"Wang","year":"2017","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.drudis.2026.104816_b0280","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.drudis.2026.104816_b0285","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jnutbio.2007.08.002","article-title":"Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon","volume":"19","author":"Tanja","year":"2008","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.drudis.2026.104816_b0290","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41573-025-01262-w","article-title":"How multispecific molecules are transforming pharmacotherapy","volume":"24","author":"Deshaies","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104816_b0295","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N\u2011acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"JACS"},{"key":"10.1016\/j.drudis.2026.104816_b0300","first-page":"1561","article-title":"Alcohol-binding sites in distinct brain proteins: the quest for atomic level resolution","volume":"35","author":"Howard","year":"2011","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.drudis.2026.104816_b0305","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.neuron.2017.10.032","article-title":"Alcohol and the brain: neuronal molecular targets, synapses, and circuits","volume":"96","author":"David","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2026.104816_b0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scisignal.128re7","article-title":"Ethanol\u2019s molecular targets","volume":"1","author":"Harris","year":"2008","journal-title":"Sci Signal"},{"key":"10.1016\/j.drudis.2026.104816_b0315","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1021\/ar900149j","article-title":"Computational studies on the interactions of inhalational anesthetics with proteins","volume":"43","author":"Vemparala","year":"2009","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.drudis.2026.104816_b0320","first-page":"1","article-title":"Systems pharmacology for investigation of the mechanisms of action of traditional Chinese medicine in drug discovery","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104816_b0325","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104816_b0330","first-page":"1","article-title":"Herb-target interaction network analysis helps to disclose molecular mechanism of traditional Chinese medicine","volume":"6","author":"Hao","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104816_b0335","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/pst.1943","article-title":"Equilibrium, affinity, dissociation constants, IC5O: facts and fantasies","volume":"18","author":"Barbet","year":"2019","journal-title":"Pharm Stat"},{"key":"10.1016\/j.drudis.2026.104816_b0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2020.586993","article-title":"Potential natural products against respiratory viruses: a perspective to develop anti-COVID-19 medicines","volume":"11","author":"Omrani","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104816_b0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2019.01132","article-title":"Closing the gap between therapeutic use and mode of action in remedial herbs","volume":"10","author":"Olives","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104816_b0350","first-page":"1","article-title":"Most-similar ligand based approach to target prediction","volume":"18","author":"Tao","year":"2017","journal-title":"BMC Bioinform"},{"key":"10.1016\/j.drudis.2026.104816_b0355","series-title":"Nutraceuticals","first-page":"315","article-title":"Target identification and polypharmacology of nutraceuticals","author":"Dorm\u00e1n","year":"2021"},{"key":"10.1016\/j.drudis.2026.104816_b0360","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1002\/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3","article-title":"Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors","volume":"37","author":"Mammen","year":"1998","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.drudis.2026.104816_b0365","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-chembioeng-100722-112440","article-title":"Designing multivalent and multispecific biologics","volume":"15","author":"Jennifer","year":"2024","journal-title":"Ann Rev Chem Biomol Eng"},{"key":"10.1016\/j.drudis.2026.104816_b0370","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1021\/bc900438a","article-title":"Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles","volume":"21","author":"Tassa","year":"2009","journal-title":"Bioconj Chem"},{"key":"10.1016\/j.drudis.2026.104816_b0375","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/cb6003788","article-title":"Selective tumor cell targeting using low-affinity, multivalent interactions","volume":"2","author":"Carlson","year":"2007","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2026.104816_b0380","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.1021\/acs.analchem.0c00092","article-title":"Impact of antigen density on recognition by monoclonal antibodies","volume":"92","author":"Bar","year":"2020","journal-title":"Anal Chem"},{"key":"10.1016\/j.drudis.2026.104816_b0385","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev-biochem-060713-035314","article-title":"Demystifying heparan sulfate\u2013protein interactions","volume":"83","author":"Xu","year":"2014","journal-title":"Ann Rev Biochem"},{"key":"10.1016\/j.drudis.2026.104816_b0390","series-title":"Pharmacology and Therapeutics","first-page":"457","article-title":"Acid reflux and ulcer disease","author":"Mejia","year":"2009"},{"key":"10.1016\/j.drudis.2026.104816_b0395","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-1759(98)00069-6","article-title":"From absolute to exquisite specificity. Reflections on the fuzzy nature of species, specificity and antigenic sites","volume":"216","author":"Regenmortel","year":"1998","journal-title":"J Immunol Methods"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:45:39Z","timestamp":1791258339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":79,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002217"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104816","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strength of weakness in molecular interactions: toward transient medicines in drug discovery","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104816","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104816"}}